Outcomes of basiliximab vs alemtuzumab induction in kidney allograft recipients with matched immunological Profiles: A retrospective cohort study

Figure 2 The treatment effects of alemtuzumab induction compared to basiliximab induction (adjusted for confounding factors including propensity scores, primary kidney disease and pre-emptive transplant rate) along with the corresponding 95%CI. Estimates were calculated using various statistical methods based on the nature of the outcome variable. CMV: Cytomegalovirus; DCGL: Death-censored graft loss; EBV: Epstein-Barr virus; eGFR: Estimated glomerular filtration rate; GN: Glomerulonephritis; NS: Not significant. ¹Estimated using linear regression. ²Odd ratio by binary logistic regression. ³Hazard ratio by Cox proportional hazard model.